{
    "clinical_study": {
        "@rank": "137804", 
        "arm_group": {
            "arm_group_label": "Preparative", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will\n      establish engraftment of donor hematopoietic cells with acceptable early and delayed\n      toxicity in patients with immune function disorders.  A regimen that maximizes host immune\n      suppression is expected to reduce graft rejection and optimize donor cell engraftment."
        }, 
        "brief_title": "Immune Disorder HSCT Protocol", 
        "condition": [
            "Immune Deficiency Disorders:", 
            "Severe Combined Immunodeficiency", 
            "Chronic Granulomatous Disease", 
            "X-linked Agammaglobulinemia", 
            "Wiskott-Aldrich Syndrome", 
            "Hyper-IgM", 
            "DiGeorge Syndrome", 
            "Chediak-Higashi Syndrome", 
            "Common Variable Immune Deficiency", 
            "Immune Dysregulatory Disorder:", 
            "Hemophagocytic Lymphohistiocytosis", 
            "IPEX", 
            "Autoimmune Lymphoproliferative Syndrome", 
            "X-linked Lymphoproliferative Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Agammaglobulinemia", 
                "Chediak-Higashi Syndrome", 
                "Common Variable Immunodeficiency", 
                "DiGeorge Syndrome", 
                "Granulomatous Disease, Chronic", 
                "Immunologic Deficiency Syndromes", 
                "Immune System Diseases", 
                "Lymphohistiocytosis, Hemophagocytic", 
                "Wiskott-Aldrich Syndrome", 
                "Severe Combined Immunodeficiency", 
                "Genetic Diseases, X-Linked", 
                "Lymphoproliferative Disorders", 
                "Granuloma", 
                "Autoimmune Lymphoproliferative Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  </= 21 years of age\n\n          -  Performance status >/= 40\n\n          -  DLCO >/= 40%\n\n          -  LVEF >/=40% or LVSF >/=26%\n\n          -  Serum creatinine < 2x ULN\n\n          -  Liver enzymes </= 5x ULN\n\n          -  Negative pregnancy test\n\n          -  Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6\n             matched unrelated UCB, 7-8/8 matched unrelated BM, double cord)\n\n        Exclusion Criteria:\n\n          -  Known diagnosis of HIV I/II\n\n          -  Pregnant or breastfeeding\n\n          -  Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting\n             alemtuzumab\n\n          -  Uncontrolled viral infection within 1 week prior to starting alemtuzumab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821781", 
            "org_study_id": "201301135"
        }, 
        "intervention": {
            "arm_group_label": "Preparative", 
            "description": "Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF", 
            "intervention_name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Melphalan", 
                "Thiotepa", 
                "Fludarabine", 
                "Fludarabine monophosphate", 
                "Alemtuzumab", 
                "Campath 1G"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Immune deficiency", 
            "Immune disorders", 
            "Immune dysregulatory", 
            "Reduced Intensity", 
            "Alemtuzumab", 
            "Campath"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "Bednarski_J@kids.wustl.edu", 
                "last_name": "Jeffrey Bednarski, MD", 
                "phone": "314-454-6018"
            }, 
            "contact_backup": {
                "email": "Murray_L@kids.wustl.edu", 
                "last_name": "Lisa Murray, CCRP", 
                "phone": "314-454-4240"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University"
            }, 
            "investigator": {
                "last_name": "Jeffrey Bednarski, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with donor engraftment", 
            "safety_issue": "No", 
            "time_frame": "1 year post transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821781"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Major Transplant Related Toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "1 years post transplant"
            }, 
            {
                "measure": "Time to neutrophil recovery", 
                "safety_issue": "No", 
                "time_frame": "within 100 days post transplant"
            }, 
            {
                "measure": "Number of patient with acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "180 days post transplant"
            }, 
            {
                "measure": "Number of participants with infectious complications", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }, 
            {
                "measure": "Time to immune reconstitution", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }, 
            {
                "measure": "Time to platelet recovery", 
                "safety_issue": "No", 
                "time_frame": "within 100 days post transplant"
            }, 
            {
                "measure": "Number of patients with chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }, 
            {
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}